Feverfew for preventing migraine

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 4, 2015, Pages

  Wider, Barbara ^a,b   Pittler, Max H ^c   Ernst, Edzard ^d  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF TROMSØ   (Norway)

^c Hospital for Cancer Research   (Germany)

^d UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TANACETUM PARTHENIUM EXTRACT;

ARTHRALGIA; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; JOINT STIFFNESS; MIGRAINE; MUSCLE RIGIDITY; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEP DISORDER; SYSTEMATIC REVIEW; VOMITING;

EID: 84970987121     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002286.pub3     Document Type: Review

References (56)

1. de Weerdt CJ, Bootsma HPR, Hendriks H. Herbal medicines in migraine prevention: randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine 1996;3:225-30.
2. Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von-Zepelin H-H. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention--a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia 2005;25:1031-41.
3. Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. BMJ 1985;291:569-73.
4. Murphy JJ, Heptinstall S, Mitchell JRA. Randomized double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988;2:189-92.
5. Palevitch D, Earon G, Carasso R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytotherapy Research 1997;11:508-11.
6. Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zeppelin HH. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis -- a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia 2002;22:523-32.
7. Cady RK, Goldstein J, Nett R, Mitchell R, Beach ME, Browning R. A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGesic™ M) in the treatment of migraine. Headache 2011;51:1078-86.
8. Ferro EC, Biagini AP, da Silva ÍE, Silva ML, Silva JR. The combined effect of acupuncture and Tanacetum parthenium on quality of life in women with headache: randomised study. Acupuncture in Medicine 2012;30:252-7.
9. Rafi S. Investigation of efficacy of feverfew and lavander in migraine prophylaxis. International Clinical Trials Registry Platform. http://www.irct.ir/searchresult.php?id=18776&number=1, accessed 30 January 2015.
10. Karimooy HN, Gholamnezhad Z, Talebi M. Effect of tanacetum parthenium (feverfew) in treatment of migraine headache comparing to dihydroergotamine and placebo. Pain Medicine. 2011; Vol. 12:487.
11. Kuritzky A, Elhacham Y, Yerushalmi Z, Hering R. Feverfew in the treatment of migraine: its effect on serotonin uptake and platelet activity. Neurology 1994;44 Suppl 2:A201.
12. Maizels M, Blumenfeld A, Burchetter R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache 2004;44:885-90.
13. Trader J-M. Feverfew as preventive therapy for migraine: N-of-1-trial for verification of individual efficacy. Zeitschrift fuer Allgemeinmedizin 2007;83:238-41.
14. Anderson D, Jenkinson PC, Dewdney RS, Blowers SD, Johnson ES, Kadam NP. Chromosomal aberrations and sister chromatid exchanges in lymphocytes and urine mutagenicity of migraine patients: a comparison of chronic feverfew users and matched non-users. Human Toxicology 1988;7:145-52.
15. Awang DVC. Prescribing therapeutic feverfew (Tanacetum parthenium (L.) Schultz-Bip., syn. Chrysanthemum parthenium (L.) Bernh.). Integrative Medicine 1998;1:11-3.
16. Blau JN. Towards a definition of migraine headache. Lancet 1984;1:444-5.
17. Brown AMG, Edwards CM, Davey MR, Power B, Lowe KC. Pharmacological activity of feverfew (Tanacetum parthenium (L.) Schultz-Bip.): assessment by inhibition of human polymorphonuclear leucocyte chemiluminescence in-vitro. Journal of Pharmacy and Pharmacology 1997;49:558-61.
18. Brun J, Claustrat B, Saddier P, Chazor G. Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. Cephalalgia 1995;15:136-9.
19. Burry JN. Compositae dermatitis in South Australia: contact dermatitis from Chrysanthemum parthenium. Contact Dermatitis 1980;6:445.
20. Dodick DW, Silberstein SD. Migraine prevention. Practical Neurology 2007;7:383-93.
21. Egger M, Zellweger-Zahner T, Schneider M, Junker C, Lengeler C, Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997;350:326-9.
22. Ernst E, Pittler MH, Wider B, Boddy K. Complementary Therapies for Pain Management. Edinburgh: Elsevier, 2007.
23. ESCOP European Scientific Cooperative on Phytotherapy. Tanaceti parthenii herba, feverfew. ESCOP Monographs. 2nd Edition. Stuttgart: Thieme, 2003.
24. Goadsby PJ. How do the currently used prophylactic agents work in migraine?. Cephalalgia 1997;17:85-92.
25. Hausen BM, Osmundsen PE. Contact allergy to parthenolide in Tanacetum parthenium (L.) Schulz-Bip. (feverfew, Asteraceae) and cross-reactions to related sesqiterpene lactone containing Compositae species. Acta Dermato-Venereologica 1983;63:308-14.
26. Hendriks H, Bos R, Woerdenbag HJ. The essential oil of Tanacetum parthenium (L.) Schultz-Bip. Flavour and Fragrance Journal 1996;11:367-71.
27. Heptinstall S, White A, Williamson L, Mitchell JRA. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. Lancet 1985;1(8437):1071-4.
28. Heptinstall S, Groenewegen WA, Spangenberg P, Loesche W. Extracts of feverfew may inhibit platelet behaviour via neutralization of sulphydryl groups. Journal of Pharmacy and Pharmacology 1987;39:459-65.
29. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
30. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8 Suppl 7:1-96.
31. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine, second edition. Cephalalgia 2000;20:765-86.
32. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33:629-808.
33. Jadad AR, Moore RA, Carrol D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
34. Knight DW. Feverfew: Chemistry and biological activity. Natural Product Reports 1995;12:271-6.
35. Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, et al. The cost of headache disorders in Europe: the Eurolight project. European Journal of Neurology 2012;19:703-11.
36. Makheja AN, Bailey JM. A platelet phospholipase inhibitor from the medicinal herb feverfew (Tanacetum parthenium). Prostaglandins Leukotrienes and Medicine 1982;8:653-60.
37. Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MF, Tierce J, et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache 2009;49:498-508.
38. Murch SJ, Simmons CB, Saxena PK. Melatonin in feverfew and other medicinal plants. Lancet 1997;350:1598-9.
39. Natural Standard Research Collaboration. Feverfew. Natural Standard, available at www.naturalstandard.com (accessed 4 February 2014).
40. Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ 2010;16:c3515.
41. Pareek A, Suthar M, Rathore GS, Bansal V. Feverfew (Tanacetum parthenium) L.): a systematic review. Pharmacognosy Reviews 2011;5:103-10.
42. Posadzki P, Watson LK, Alotaibi A, Ernst E. Prevalence of herbal medicine use by UK patients/consumers: a systematic review of surveys. Focus on Alternative and Complementary Therapies 2013;18:19-26.
43. Pugh WJ, Sambo K. Prostaglandin synthetase inhibitors in feverfew. Journal of Pharmacy and Pharmacology 1988;40:743-5.
44. Saranitzky E, White CM, Baker EL, Baker WL, Coleman CI. Feverfew for migraine prophylaxis: a systematic review. Journal of Dietary Supplements 2009;6:91-103.
45. Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. Cephalalgia 2013;33:289-90.
46. Sun-Edelstein C, Mauskop A. Foods and supplements in the management of migraine headaches. Clinical Journal of Pain 2009;25:446-52.
47. Taylor FR. Nutraceuticals and headache: the biological basis. Headache 2011;51:484-501.
48. Tfelt-Hansen P, Nielsen SL. Patient numbers needed in prophylactic migraine trials. Neuroepidemiology 1987;6:214-9.
49. Tfelt-Hansen P, Pascual J, Ramadan N, Dahlöf C, D'Amico D, Diener HC, et al. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia 2012;32:6-38.
50. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163-96.
51. Willigmann J, Freudenstein J. Production of a stable feverfew (Tanacetum parthenium) extract as an active substance for a pharmaceutical product. Internal document, Schaper Brummer GmbH and Co., 1999; Poster Symposium. Vienna: Society for Medicinal Plant Research; 1998.
52. World Health Organization. Headache disorders. Fact sheet N°277. http://www.who.int/mediacentre/factsheets/fs277/en/ 2012 (accessed 29 January 2014).
53. Ernst E, Pittler MH. The efficacy and safety of feverfew (Tanacetum parthenium L.): an update of a systematic review. Public Health Nutrition 2000;3:509-14.
54. Pittler MH, Vogler BK, Ernst E. Feverfew for preventing migraine. Cochrane Database of Systematic Reviews 2000, Issue 3. [DOI: 10.1002/14651858.CD002286]
55. Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD002286.pub2]
56. Vogler BK, Pittler MH, Ernst E. Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia 1998;18:704-8.